advertisement
Abstract #18346 Published in IGR 3-3
Effects of topical application of a 2% solution of dorzolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs
Cawrse MA; Ward DA; Hendrix DVAmerican Journal of Veterinary Research 2001; 62: 859-863
OBJECTIVE: To evaluate effects of topical application of a 2% solution of dorzolamide on intraocular pressure (IOP) and aqueous humor flow rate in clinically normal dogs. ANIMALS: Fifteen beagles. PROCEDURE: IOP was measured in both eyes of all dogs for three days to determine baseline values. In a single-dose study, 50 μl of dorzolamide or control solution was applied in both eyes at 7:00 a.m., and IOP was measured seven times/day. In a multiple-dose study, dorzolamide or control solution was applied to both eyes three times/day for six days, and IOP was measured four times/day during treatment and for five days after cessation of treatment. Aqueous humor flow rate was measured for all dogs fluorophotometrically prior to treatment and during the multiple-dose study. RESULTS: In the single-dose study, dorzolamide significantly decreased IOP from 30 minutes to six hours after treatment. Mean decrease in IOP during this time span was 3.1 mmHg (18.2%). Maximal decrease was detected six hours after treatment (3.8 mmHg, 22.5%). In the multiple-dose study, dorzolamide decreased IOP at all time points, and maximal decrease was detected three hours after treatment (4.1 mmHg, 24.3%). Mean aqueous humor flow rate decreased from 5.9-3.4 μl/min (43%) after treatment in the dorzolamide group. CONCLUSIONS AND CLINICAL RELEVANCE: Topical application of a 2% solution of dorzolamide significantly decreases IOP and aqueous humor flow rate in clinically normal dogs. Therefore, topical administration of dorzolamide should be considered for the medical management of dogs with glaucoma.
Dr M.A. Cawrse, The Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37901, USA
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
